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Conference Report 
Acetylsalicylic acid was first synthesised by Dr FeIix Hoffman on August 10th 1897 and 
Aspirin was born. It quickly became the best known pain killer in the world and in the 120 
years since this event aspirin has continued to attract interest, innovation and excitement.  
Set within the walls of the preserved ruins of Rudolf Virchow’s lecture hall at Charité, within 
Berlin’s Museum of Medical History, the International Aspirin Foundation’s 28th Scientific 
Conference served to facilitate international, multi-disease, multi discipline discussion about 
the current understanding of aspirin’s mechanisms of action and utility in modern medicine 
as well as ideas for future research into its multifaceted applications to enhancing global 
health.  
In addition to the delegates in Berlin 300 medical doctors at the 19th Annual Scientific 
Congress of the Chinese Society of Cardiology were able to join the cardiology sessions 
from Taiyuan, Shangxi province via a live streaming link to and from China. This led to useful 
discussion and allowed a truly international perspective to the meeting.  
The first session an update on cardiovascular disease (CVD) and stroke: East meets West 
was chaired by Professor Junbo Ge who expressed his delight at joining the conference and 
working together to tackle CVD which is now the number one killer in China. 
The disease burden of CVD and the major strategy of primary prevention for CVD in 
China - Dr Dong Zhao 
Dr Dong Zhao joined the meeting, via the live streaming link to the Chinese Society of 
Cardiology Congress in Taiyuan, and described the growing CVD burden in China and the 
primary prevention strategies used to tackle this. Dr Zhao is involved with the development 
of both Chinese and international CVD prevention guidelines. 
Cardiovascular disease (CVD) is currently the top cause of premature death in China. In line 
with the United Nation’s Sustainable development goals for 2030, China aims to reduce by a 
third all premature death from non-communicable causes1. In 2012 CVD was responsible for 
41 % of all urban deaths and 39% of rural deaths2. This challenge is heightened by the fact 
that the rate of mortality from ischemic heart disease (IHD) has risen dramatically over the 
last 2 decades; it was the seventh leading cause of life lost in 1990 but by 2010 it had 
jumped up to be the second cause 3. This pattern is expected to continue with the estimated 
numbers of people with IHD in China more than doubling from 8.1 million in 2010 to 22.6 
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million in 20302,3,4. Stroke statistics show an improved survival rate and reduced disability, 
3,5  however the number of people having a stroke is still expected to increase from 8.3 
million in 2010 to 32 million in 2030. China ranks in the top three for premature deaths from 
stroke among the G20 countries 3, whilst aging and population growth may account for at 
least half of the increase in CVD, lifestyle factors also play a key role in the current and 
future CVD epidemic. 
Primary prevention of CVD is particularly important in China because in over 70% of 
individuals experiencing a first Coronary Heart Disease (CHD) event, death occurred outside 
of the hospital setting without a chance for secondary prevention6. With cardiac arrest 74% 
of cases occurred at home. Primary prevention of CVD in China is therefore a top priority 
strategy for reducing these premature deaths especially the potential to influence lifestyle 
factors (e.g. smoking, diet, weight and activity levels) and reduce risk factors such as high 
blood pressure, high cholesterol and control diabetes. 
Dr Zhao explained that CVD risk assessment is important in order to identify those at high-
risk in the Chinese population without current CVD and help them to understand the whole 
profile of their CVD risk factors in order to be able to provide an individualised CVD risk 
management plan. To be able to carry out CVD risk assessment a CVD risk prediction 
model based on long term observational studies and risk assessment tools are required as 
well as relevant recommendations in guidelines. Predictive models developed in one 
geographical area or ethnic population may not be suitable for other populations and 
regions. Risk assessment methods such as the Framingham CVD risk score which has a 
homogeneous nature to its study population cannot be simply extrapolated to other settings. 
Specific tools of risk assessment for the Chinese population have been developed based the 
Chinese Multi –provincial cohort study. 
The 2012 China National Plan for Non-Communicable diseases [NCD] prevention and 
treatment7 has clear targets for CVD prevention.  Both the 2016 China guidelines of 
dyslipidemia management and the 2017 Chinese guidelines for CVD prevention (soon to be 
published) have new recommendations for risk assessment in China.  
The 2016 China expert consensus advocates that for individuals with a ten year 
arteriosclerotic cardiovascular disease (ASCVD)8 risk of greater than or equal to 10%, 
aspirin should be used for the primary prevention of CVD. Doctors in China need to identify 
those with a high CVD risk and provide early treatment for their CVD risk factors. The 
updated protocol of CVD risk assessment in China has provided a reasonable tool to assist 
clinicians in achieving this. Busy clinics in China can sometimes stand in the way of finding 
time to carry out CVD risk assessment; the greatest challenge therefore will be finding ways 
to effectively implement these guidelines into CVD prevention practice in China. 
Antiplatelet therapy for stroke prevention in China – Professor Yongjun Wang 
Professor Yongjun Wang from Beijing Tiantan Hospital presented from China on antiplatelet 
therapy for stroke prevention in China.  Stroke is a major burden in China; from 2010 stroke 
became a leading cause of death and disability in China and mortality from stroke is 5 times 
higher in China than it is in the USA3,9. According to a national population based survey in 
2013, the prevalence of stroke in China was 1114.8 per 100, 000 people and its prevalence, 
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incidence and mortality rates were significantly higher in rural areas compared with urban 
areas10. More than 70% of stroke patients have either ischemic stroke or TIA10 .  
The Chinese clinical guidelines for the secondary prevention of ischemic stroke and TIA 
recommend an optimal dosage of aspirin between 75 and 150 mg/day. A combination of 
aspirin and clopidogrel for 21 days is recommended to patients with minor stroke or high-risk 
TIA within 24 h of onset 11. These recommendations are based on the CHANCE trial12. 
The rationale behind the randomised controlled CHANCE trial was to find the “sweet spot” or 
balance point of efficacy and safety for dual antiplatelet therapy in stroke. After three 
previous trials MATCH 2004, PRoFESS 2008 and SPS3 2012 had all failed to increase 
efficacy but had increased the risk of bleeding, CHANCE, which randomised 5170 patients 
from 114 hospitals focused on early, short-term, optimized dual antiplatelet therapy (within 
24 hours) to reduce the risk of new stroke at 3 months for clopidogrel-aspirin treatment in 
acute minor stroke or high-risk TIA. After a big data analysis based on 90, 000 patients in 
other trials, several strategies were found that may improve the efficacy, without increase in 
the risk of bleeding, of antiplatelet therapy. This formed the rationale behind CHANCE; 
1) Intensive antiplatelet therapy should be initiated within 24 hours. 
2) High-risk non-disabling patients may have high risk of ischemic events but low risk of 
bleeding and are therefore the appropriate target population. 
3) An appropriate treatment strategy with a loading dose of clopidogrel 300g given as 
soon as possible and then dual antiplatelets for 21 days should be used.  
The hypothesis was that this early, short-term, optimized dual antiplatelet therapy could be 
an effective strategy with a low risk of bleeding13. CHANCE showed an early benefit of 
clopidogrel-aspirin treatment in reducing the risk of subsequent stroke which persisted for 
the duration of the 1-year of follow-up12. They also found in patients treated within 12 hours, 
the combination of clopidogrel and aspirin was more effective than aspirin alone in reducing 
the risk of recurrent ischemic stroke during the 90-day follow-up and did not increase the 
haemorrhagic risk 14. Clopidogrel-aspirin treatment may have a benefit of reducing stroke 
risk outweighing the potential risk of increased bleeding especially within the first 2 weeks 
compared with aspirin alone in patients with minor stroke or TIA15. In addition two-week 
combination therapy may be enough for minor stroke or high-risk TIA. 
The CYP2C19 genotype and clopidogrel responsiveness was also investigated in the 
CHANCE trial and it was discovered that the use of clopidogrel plus aspirin compared with 
aspirin alone reduced the risk of a new stroke only in the subgroup of patients who were not 
carriers of the CYP2C19 loss-of-function alleles. In CHANCE it was found that nearly 59% of 
patients were carriers of the CYP2C19 loss-of-function alleles 16. These findings support a 
role of the CYP2C19 genotype in the efficacy of this treatment. Individualised antiplatelet 
therapy according to genotype will help target treatment in the future. 
The efficacy of ticagrelor is however not affected by CYP2C19 and this led to the 
development of another RCT, the PRINCE trial, in order to assess 90-day platelet reactivity 
for ticagrelor-aspirin treatment, compared with clopidogrel-aspirin treatment in acute minor 
stroke or high-risk TIA within 24 hours after onset. The interim analysis suggests that looking 
at PRU (platelet reactivity units) and HOPR (high on-treatment platelet reactivity); there may 
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be a positive trend for better efficacy for those treated with the ticagrelor and aspirin 
combination. 
Professor Wang concluded that antiplatelet therapy is easy to use, inexpensive and well 
tolerated; adherence however is not optimal with a decline in antiplatelet use from 81% at 
the time of hospital discharge to 66% post-stroke17.  
Acute effects of aspirin in TIA and stroke – Professor Peter Rothwell 
Professor Peter Rothwell, Head of the Centre for the Prevention of Stroke and Dementia in 
Oxford, UK took the delegates through the role of aspirin in acute TIA and minor stroke. 
There is an acute or early risk of a major stroke occurring after TIA or minor stroke of around 
10% unless appropriate treatment is given 18,19,20,21. The first hours after a minor stroke or 
TIA are therefore considered an emergency. Unfortunately many patients after a TIA or 
minor stroke wait more than 24 hours to see their GP, the length of the delay depends on the 
day of the week, with weekends leading to a longer wait22. 
Despite UK public education such as the FAST campaign (Face, Arms Speech, Time 
https://www.stroke.org.uk/take-action/recognise-signs-stroke), people are still not seeking 
medical attention soon enough 23. Unlike a suspected heart attack where the American Heart 
Association and British Heart Foundation advise self-medication with an aspirin, official 
website advice for a suspected TIA or stroke vary with either no recommendation or advice 
to check with a doctor before taking aspirin. Pre-hospital self-administration of aspirin tends 
to be discouraged after stroke because of concerns about the possible risk of intracerebral 
haemorrhage. This fear is unfounded as haemorrhage is a rare cause of TIA symptoms and 
is responsible for less than 5% of minor strokes. People should be encouraged to seek 
immediate medical attention and with transient neurological symptoms self-administration of 
aspirin may also be appropriate especially where access to medical care maybe delayed.  
There are few randomised trials on the effect of aspirin on the risk of early recurrent stroke 
after TIA and minor stroke and no data on severity. Observational studies do however 
suggest early substantial benefits.    
The EXPRESS study which was not randomised but a before and after study showed an 
80% reduction of recurrent stroke when patients were seen promptly and given aspirin, 
started on a statins and BP lowering agents 24,25. Of these aspirin is hypothesised to produce 
much of the acute benefit24. The severity of recurrent cerebral events was also reduced in 
EXPRESS.  
Due to the absence of published randomised evidence, data was extracted and re-analysed 
from all available previous trials of aspirin versus placebo for secondary prevention after TIA 
or ischaemic stroke26. This showed that the acute benefits of aspirin have been 
underestimated. The researchers found that if aspirin is given early after TIA and minor 
stroke there are less severe recurrent events as well as far fewer events.   
Professor Rothwell ended his presentation recommending that the general public should 
self-administer aspirin after TIA in the same way that they take aspirin for chest pain. Timely 
medical treatment with aspirin as a key intervention is important after all possible TIAs or 
minor stroke. Aspirin should be self-medicated after an unknown “funny turn”, it is widely 
available, costs virtually nothing and there is no major bleeding issue after transient events.  
5 
 
5 
 
Primary prevention in the US and Europe and forthcoming trials – Professor Mike 
Gaziano  
At the other end of the spectrum Professor Gaziano, a preventive cardiologist and 
internationally recognised chronic disease epidemiologist from Boston, USA, spoke of his 
work in aspirin primary prevention trials including the landmark Physicians Health Study 
(PHS), the large-scale Women’s Health Study (WHS) and currently the ARRIVE trial. 
Whilst the benefit of aspirin antiplatelet therapy has been clearly demonstrated for people 
with previous CVD27 this risk/benefit equation is more complex in primary prevention; where 
individuals are at risk of an initial cardiovascular disease but have not yet had an event.  
The United States Preventative Services Task Force (USPSTF)28 has conducted a 
systematic review of the effect of aspirin in the primary prevention of CVD. It is worth noting 
the primary prevention trials were mostly in people of European descent and the risk to 
benefit ratio may differ in other populations. USPSTF used a series of scholarly works to 
underpin their decisions about aspirin in the primary prevention of CVD and colorectal 
cancer (CRC). They looked at the number of events prevented versus the number of events 
caused (e.g. GI bleeding) and considered absolute number of events, all risk in net life years 
and quality of life years gained. This was a multiple risk strategy. Following their review the 
USPSTF has recommended initiating low dose aspirin use for the primary prevention of CVD 
and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are 
not at risk of bleeding, have a life expectancy of at least 10 years, and are willing to take low-
dose aspirin for at least 10 years. They also state that in the 60-69 year age group the 
decision to initiate aspirin should be an individual one and that there is not enough available 
evidence to recommend, for or against, the use of aspirin in the prevention of CVD and CRC 
in those younger than 50 years and 70 years or above.  
It is the action of aspirin on platelet function that works to prevent CVD events that is also 
responsible for its side effect of bleeding risk. This bleeding risk falls into two main 
categories; gastrointestinal (GI) bleeding and intracranial bleeding. Risk of bleeding can 
increase with a person’s age, gender, medication use and CVD risk factors29. 
Whilst numerous trials have been carried out on the role of aspirin in acute treatment and the 
secondary prevention of CVD there are relatively few in the area of primary prevention and 
most have been done among those at lower risk of CVD events. This is because of the large 
scale required for these studies and the need for long term follow up. Several ongoing 
primary prevention trials are however now under way and will come to fruition over the next 
few years which will help to give more insight into the use of aspirin in populations where the 
risk of CVD is higher than the general population.  ARRIVE (Aspirin to Reduce Risk of Initial 
Vascular Events) tests aspirin 100 mg daily in those with moderate to high risk of a CVD 
event results are expected 2018. ARRIVE is being conducted mainly in Europe. ASPREE 
Aspirin in Reducing Events in the Elderly looks at patients over 70 years and is being 
conducted in Australia and the United States, ASCEND is a study based in the UK testing 
low dose aspirin in diabetics without known CVD and ACCEPT-D tests low dose aspirin and 
simvastatin in diabetics.  These trials will provide critical information to refine 
recommendations for different segments of the population. 
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People should be encouraged to talk with their clinician about starting low dose aspirin. 
Providers also need education on how to apply risk assessment tools and make calculations 
regarding the use of low dose aspirin. In this age of empowerment patients can help with this 
dialogue. Tools are emerging that help patients own more of their health data and contribute 
to decisions about their treatment. An assessment of CVD risk, total mortality, cancer risk 
and bleeding risks are necessary when considering aspirin in primary prevention.  Therefore, 
unlike acute care, where a more parental role is used to recommend treatment, in primary 
prevention we need to empower patients to make the decision. In an acute event the patient 
can see the benefit of the therapy and understands the risk but in primary prevention the 
patient often feels well and yet their blood pressure and cholesterol are raised. They might 
need to take a statin, aspirin and blood pressure medication. All of which requires active 
participation from the patient. “The person won’t thank you for the heart attack or stroke they 
didn’t have but they may blame you for a bleed whilst on aspirin”. This is a difficult paradigm 
and a complex construct for the clinician to manage.  
Professor Gaziano called for a consideration for wider use of low dose aspirin in both 
primary and secondary prevention which could potentially save hundreds of thousands of 
lives annually and prevent millions of CVD and cancer events around the world.  
During the discussion time the question of what is low dose aspirin in primary prevention 
was raised. Overall there is a lack of data to agree an exact dose but when using aspirin for 
primary prevention compliance over a long time period needs to be considered and it is 
therefore better to be within an effective dose range rather than on the margin of the dose 
range; 100 mg a day seems to be effective for most people. However a one dose fits all 
approach may not be right. There is currently no tailoring to weight and physical 
characteristics and this is probably what is needed especially where compliance is an issue 
leading to an intermittent rather than continuous antithrombotic effect. Personalised 
medicine will probably be the future with precise targeting of medication. This is an area of 
active research currently with a large trial in secondary prevention testing two doses head to 
head.  
Stopping aspirin for surgery was also discussed. In many instances this is done more for 
surgeons benefit as the operation will be approximately 10% shorter but is not usually 
necessary for the patient. Surgery puts the patient into a very prothrombotic state so 
stopping aspirin is not helpful.  
Delegates asked how long patients should be on aspirin. It was felt overall that in primary 
care in general there should be ongoing dialogue regarding CVD risk, cancer risk, life 
expectancy and bleeding risks on aspirin as these all change over time. Therefore at fairly 
regular intervals medications need to be reviewed with the patient in order to update where 
the patient is on the risk to benefit spectrum.  
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The oncology session, chaired by Professor Ruth Langley, looked at the evidence for aspirin 
in cancer prevention and treatment and the challenges in communicating the benefits and 
risks of aspirin to the wider population.  
Aspirin for the Primary Prevention of Colorectal Cancer- Professor Andrew Chan 
Professor Andrew Chan, who heads the Clinical and Translational Epidemiology Unit at 
Massachusetts General Hospital and is a Professor of Medicine at Harvard Medical School, 
spoke about the role of aspirin for the primary prevention of colorectal cancer (CRC). He 
explained that in some ways this should be a public health consideration in the context of 
aspirin’s role in multiple diseases rather than any single individual disease. An improved 
identification of those in whom the protective effect of aspirin outweighs any harms will be 
important and this precision medicine approach may emerge as further understanding of 
aspirin’s mechanism of action become clearer.  
Colon cancer is one of the most preventable cancers in the developed world however the 
current methods of prevention do have limitations 30. There is however a substantial weight 
of evidence supporting aspirin in CRC prevention starting with research carried out in the 
1980s and continuing through to the current day. The data includes case control and cohort 
studies as well as some randomised controlled trials (RCTs).  Current cancer screening 
methods are successful but there are limitations and they are resource intensive, limiting its 
potential in many populations. To investigate the potential for precision medicine, Professor 
Chan’s team leveraged data from two large population based cohorts. From a pooled-
analysis of ten cohort and case-control studies aspirin was shown to reduce the risk of CRC 
by 29%31.  Further data has come from a secondary analysis of RCTs; a meta-analysis of 
four RCTs suggested that aspirin treatment for five or more years at doses of at least 75mg 
daily reduced long-term CRC risk by 24%32. It appeared that a significant reduction in risk 
was not observed until at least a decade of use.  Aspirin use is however associated with 
clear hazards – especially gastrointestinal bleeding and therefore there is a critical need for 
a precision medicine approach. 
The weight of the evidence is so strong that the influential USPSTF released a 
recommendation which incorporates CRC prevention into the rationale for recommending 
routine aspirin use among patients with cardiovascular risk factors.  Although this guideline 
doesn’t speak to a recommendation in the absence of CVD prevention, it is a milestone in 
that, other than tamoxifen in high risk breast patients, this is the first medication 
recommended for cancer prevention. 
Professor Chan explained that a definitive RCT testing long term daily aspirin at a range of 
doses for its effect on CRC is difficult to carry out due to the large number of subjects and 
the length of follow up that would be required.  Instead RCTs designed to test the effect of 
aspirin on colorectal adenomas, the precursor to most CRCs, have been carried out and 
have provided positive data for aspirin in chemoprevention. These include the Aspirin/Folate 
Polyp Prevention Study (AFPPS), Association pour la Prévention parl’Aspirine du Cancer 
Colorectal (APACC), Cancer and Leukemia Group B (CALGB), the United Kingdom 
Colorectal Adenoma Prevention (ukCAP) trial  and the Japan Colorectal Aspirin Polyps 
Prevention (j-CAPP) trial.  
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In future years additional RCTs such as ARRIVE, ASCOLT, ASPIRED, ASPREE, CAPP3, 
SeAFOod and the continued collection of long term outcome data from completed trials are 
expected to add to the growing weight of evidence supporting the use of aspirin for the 
prevention of CRC.  
Professor Chan proposed that aspirin probably works via an integrative multi-pathway model 
rather than any single dominant pathway for its mode of action. As our understanding of 
aspirin’s anti-cancer mechanism grows it may be possible to develop molecular biomarkers 
(using tissue, urinary or genetic biomarkers) that will help to stratify those most likely to 
benefit from taking long term aspirin. Pathways for finding potential biomarkers include the 
inhibition of prostaglandin-endoperoxide synthase (PTGs), the Wnt/-catenin signalling axis, 
aspirin’s anti-inflammatory properties (including host immune response modulation) and 
platelet mediated effects.  
As well as these effects on cancer initiation, aspirin may also inhibit cancer progression. A 
number of studies have shown aspirin use to lower cancer specific CRC mortality in patients 
with CRC 33,34,35,36,37,38,39. This action may be explained by aspirin’s effect on PG synthesis or 
Wnt signalling or other mechanisms such as the PIK3CA mutant. Biomarkers such as the 
PIK3CA mutant may be able to be used in the future to predict responsiveness to aspirin 
treatment.  
Professor Chan concluded that there is overwhelming evidence to support the 
chemopreventative benefit of aspirin on CRC. Hazards associated with long-term aspirin use 
such as GI bleeding make strategies for risk stratification important and work around 
aspirin’s mechanisms of action may help to target its application to specific groups. Aspirin 
has an integrative multi-pathway model for its mode of action and it may be possible to use 
these pathways to develop mechanistic biomarkers for personalized risk stratification. 
Molecular and generic markers in prostaglandin and inflammatory pathways hold promise. 
Such biomarkers could then be translated clinically to predict who will benefit from aspirin 
chemoprevention and treatment and fulfil the promise of a precision medicine approach.  
Lynch syndrome and experience of implementing secondary prevention – Professor 
Sir John Burn 
Lynch syndrome and experience of implementing secondary prevention – Professor Sir John 
Burn 
Lynch syndrome is an important area of investigation for aspirin and its cancer preventative 
effects because it provides a genetical sub group of people who can be specifically treated 
with the aim of benefiting them and informing the research into aspirin’s mechanism in 
cancer prevention as a whole. 
Professor Sir John Burn presented an analysis of cancer rates carried out at the tenth year 
of the CAPP2 trial which showed aspirin to have a protective effect against cancer 40. A 
secondary analysis of the impact of obesity revealed those that individuals who had the 
genetic predisposition for cancer and were overweight were more than twice as likely to 
develop CRC. This effect was partially abrogated in the aspirin arm of the study when 
compared with placebo possibly due to the anti-inflammatory role of the 600 mg dose used 
in the study. The ten year blinded follow up of this study is expected to confirm that there is a 
protective effect from aspirin use and that this effect is a truly preventative effect rather than 
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suppressing tumours which may then later emerge. In most cases the aspirin was 
discontinued in CAPP2 before the impact on cancer incidence. This suggests an impact on 
precancerous legions (possibly by enhanced apoptosis or immune clearance of defective 
stem cells) rather than a direct effect on malignant cells.  
CAPP3 a randomised dose non-inferiority trial will compare the 600 mg dose of aspirin, 
shown to be effective in CAPP2, with a 300 mg and 100 mg daily dosing schedule. Results 
should be available from 2023 with an adverse events assessment in 2020. In addition a 
biobank will assess frame shift peptide antibody titres a possible biomarker of subclinical 
cancer development. 
Aspirin for cancer prevention and cure – Is the time now?  Professor John Chia 
Professor Chia described the twin challenges of cardiovascular disease and cancer facing 
Asia with its current burgeoning populations. Over the coming decades the economic burden 
of these two major diseases is expected to cost in excess of a trillion dollars 41. 
Professor Chia reviewed past and ongoing trials of aspirin in cancer and asked if the 
widespread adoption of aspirin as a chemo preventative agent in Asia, is an idea whose 
“time has come.” 
As well as a primary prevention and treatment role for CRC aspirin is also creating interest 
for its role in tertiary cancer prevention via its synergy with immunotherapy. The 2017 ESMO 
conference was dominated by immune oncology and headline press currently are the 
immune check point inhibitors such as pembrolizumab and nivolumab.  Immunotherapy is 
set to become the fourth pillar of cancer therapy along with surgery, radiotherapy and 
chemotherapy.   
Aspirin now also has a story to tell in combination with these new compounds as it appears 
to have a synergistic effect with them. Aspirin in combination with immunotherapy is of key 
interest and it is being included in some immune check point inhibitor trials. Aspirin also 
potentially enhances adoptive T cell therapy and this unfolding story is thought to be due to 
the fact platelets potentially stop T cells from killing cancer cells. Aspirin appears to allow the 
immune system access to kill cancer cells. These examples of aspirin’s exciting and 
potentially synergistic role in cancer immune therapy created a lot of discussion among the 
delegates at the meeting.  
Discussion about clinical implications – Professor Ruth Langley 
The discussion focused on how best to communicate aspirin’s benefits and risks and its role 
in cancer prevention both primary and secondary, as well as tertiary/adjuvant treatment of 
micrometastatic disease42. The concept of chemoprevention for cancer is relatively novel 
and particularly in primary prevention, is a fairly complex concept to grasp particularly as the 
effects of aspirin take about 10 years to become apparent and have to be balanced with the 
risks of potential toxicity particularly serious bleeding. The challenge of explaining the risks 
and benefits to patients was discussed and it was felt that the development of a measurable 
biomarker analogous to cholesterol or blood pressure in cardiovascular disease may be 
needed for therapeutic cancer prevention to be successful and implemented.   
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The group agreed that these complicated messages with many factors to communicate 
represented a major challenge. Social media with its short punchy lines may not be 
appropriate. Instead it was felt that primary care clinicians could be an important target for 
education and information about the risks and benefits of aspirin. Others however felt that in 
the modern 21st century we need to move away from a professional telling you what to do 
and that people need to make their own informed decision. The evidence is there, it has 
been 30 years in making and individuals can decide to reduce their CVD and cancer risk in 
exchange for a small risk of side effects. 
Other issues considered included the fact that aspirin is not considered to be an oncology 
drug and meetings and conferences are arranged by tumour site which may be a challenge 
for chemoprevention. Understanding the anti-cancer mechanism(s) of action of aspirin will 
be crucial to maximising its clinical utility in the future.  
The science session chaired by Professor Lina Badimon explored some of the excellent 
work currently being carried out to enhance our understanding of aspirin’s mode of action 
and pharmacological profile.  
The aspirin-sensitive platelet lipidome: beyond thromboxane A2 – Professor Valerie  
O’Donnell 
Valerie O’Donnell is a Professor of Biochemistry and Co-Director of the Systems Immunity 
Research Institute in Cardiff.  Professor O’Donnell uses new generation mass spectrometry 
to characterise cellular lipidomes. Aspirin’s cardioprotective effects result from it blocking 
cyclooxygenase-1 (COX-1) dependent generation of the pro-thrombotic lipid, thromboxane 
A2 (TXA2). In her work Professor O’Donnell uses high resolution mass spectrometry 
techniques to gain insight into the behaviour of cellular lipidomes in health and disease. By 
defining the aspirin sensitive platelet lipidome and investigating how platelet lipids change 
with aspirin treatment we can further enhance the diagnosis and treatment of patients. In 
particular Professor O’Donnell has set out to gain answers to the following question: 
 How many lipids do platelets contain? 
 Can we use this information to discover new bioactive lipids from platelets? 
 How do lipids vary over time in the same people? 
 What is the effect of gender on platelet lipids? 
 How variable are aspirin responses in the same people over time? 
Understanding the total diversity and number of individual lipids in cells as well as how they 
alter during activation of cells and differ between individuals will help improve the 
understanding of lipid biochemistry and help find new targets for drug therapy and improve 
the identification of lipid biomarkers in cohort samples. In particular this work will help to 
identify bioactive lipids that are usually present in very small amounts and therefore not 
routinely detected.  
Following some innovative research work using mass spectrometry, informatics, statistics 
and the development of some in house software to manage data, Professor O’Donnell and 
her team began to characterize the platelet aspirin-sensitive lipidome and use this to 
uncover lipidomic networks43. They found that the human platelet lipidome is complex and 
that major changes occur following the ingestion of aspirin. They found large numbers of 
lipids appeared on activation and of these in excess of 70% were sensitive to aspirin. There 
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is a lot of potential discovery science in finding new lipids and this represents an important 
opportunity for the future. 
After an initial pilot in 3 genetically different donors a current project is underway looking at 
30 volunteers over a six month period during which they were given repeated aspirin. The 
results of this work are expected soon. The research is still at the stage of trying to 
understand what goes on in healthy people rather than exploring effects in disease. 
 
PK/PD determinants of the interindividual variability in the antiplatelet response: 
aspirin “resistance” revisited – Professor Bianca Rocca 
Professor Bianca Rocca from the pharmacology Institute of the Catholic University School of 
Medicine in Rome discussed the pharmacokinetic (PK) and pharmacodynamic (PD) 
determinants of the interindividual variability in the antiplatelet response and aspirin 
“resistance”.  
She explained that many variables contribute to the clinical outcome, starting from the 
prescribed dose of each drug: the prescribed dose of a drug may differ from that actually 
administered, the dose/drug concentration at the site of action and the intensity of 
pharmacological effect can be affected by physiological (e.g. age, renal function etc.), 
pathological factors (e.g. kidney or liver dysfunctions), genetic variation, drug-drug 
interactions and the development of resistance or tolerance.  
Understanding the determinants of interindividual variability in drug responsiveness and 
reducing it can improve a drug’s effectiveness in real world settings. If reliable biomarkers 
can be found a greater understanding of determinants of drug variability can be developed, 
and this will inform the development of the personalised, precision or stratified medicine.  
Serum TXB2 ex vivo is for example a pharmacodynamic biomarker supported by the 
European Medicines Agency, which can be used to check the efficacy of new aspirin 
formulations44. 
Interindividual variability in response applies to aspirin as well, and seems to be associated 
with its PD and/or metabolic disposition, using the correct assay appears crucial for 
identifying determinants of variability and designing new regimens. Identifying determinants 
of variability in aspirin response is relevant in hypothesizing and testing new ways of 
administering  an ‘old’, effective (and cheap) drug in selected clinical conditions. 
Shortening the dosing interval rescues the impaired antiplatelet effect of low-dose aspirin in 
acute or chronic settings of high platelet turnover. A reduced bioavailability may benefit from 
doubling the once daily dose. The clinical translation of these PD/PK findings will need 
adequately sized randomised trials comparing improved versus conventional regimens.  
Essential thrombocythaemia (ET)  (a myeloproliferative neoplasm which causes increased 
platelet generation and an increased risk of thrombotic complications) is one example where 
the dose of aspirin may need to be altered and algorithms for treating ET at intermediate and 
high risk of thrombosis have been developed with  twice daily aspirin being considered for 
certain patients45. 
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Another area where aspirin dosing may require temporary variation is in the acute setting  
soon after cardiac surgery for CABG, unless the bleeding risk is high, work has now shown 
that a twice daily low dose aspirin regimen may be required, especially in the first 3 months 
post-surgery 46. 
The global obesity epidemic is another issue for drug pharmacokinetics with a multitude of 
changes take place and a speeding up metabolism and excretion. The net effect of which on 
a single drug is variable and unpredictable especially for lipophilic drugs.  Aspirin is lipophilic 
and body weight has been shown to reduce aspirin efficacy in inhibiting platelet 
thromboxane47,48. The area of obesity and drug pharmacokinetics is currently a big gap in 
knowledge especially in patients with cardiovascular diseases and with a BMI above 35 or 
40 kg/m2. 
Interindividual variability in response to aspirin is an important issue and is associated with 
its pharmacodynamics and pharmacokinetics. Research into this area of pharmacology 
using the correct assays will be crucial in order to identify the determinants of this variability 
and design new regimens. 
What is the risk of bleeding? – Professor Peter Rothwell 
Professor Rothwell explored the risk of bleeding in the secondary prevention setting where 
lifelong antiplatelet treatment is recommended after a vascular event. Antiplatelet drugs 
increase the risk of a patient experiencing a major bleed in particular upper-gastrointestinal 
(GI) bleeding49.  These potential harms include haemorrhagic stroke and GI bleeding. The 
risk of haemorrhagic stroke is largely offset by the reductions in ischaemic stroke and the 
HOT trial showed that optimising blood pressure control can help to minimise the 
haemorrhagic strokes caused by aspirin. In the case of GI bleeding the majority of people do 
not have serious sequelae with this if they are under the age of 65 years. Proton pump 
inhibitors (PPI) do however reduce the risk of a GI bleed by 70-90%50 but co-prescription is 
not currently routine practice. Secondary prevention clinical guidelines make no 
recommendations on PPI use and although some consensus statements do advocate GI 
protection in “high risk” patients the definition of who is high risk varies. The low uptake of 
PPI use may be due to concerns about long-term harm from PPIs and variability in the 
definition of who the “high risk” population for bleeding on aspirin constitutes. The evidence 
behind antiplatelet therapy in secondary prevention is based on early randomised trials in 
patients under 75 years. The mean age for a myocardial infarction is however 75 years with 
the mean age for TIA and stroke 65 years. It is estimated that 50% of patients taking 
antiplatelets are now age 75 and older. 
The Oxford Vascular Study (OXVASC) is a prospective, population based study of all 
incident and recurrent acute vascular events including TIA, ischaemic stroke and myocardial 
infarction (MI). It is based on a population of 92,728 people. In OXVASC 3166 patients of 
which 1094 had an MI and 2072 had a TIA/ischaemic stroke were studied and all were 
treated with antiplatelet medication. At one year 2301 (89%) were on antiplatelet treatment 
and 852 (33%) were taking a PPI or H2 antagonist. Half (1582 (50%)) of the patients were 
75 years or older. The study found that during 13,509 years of patient follow-up there were 
405 first bleeding events and of these 162 were upper GI51.  The risk of having a major bleed 
increased steeply with age and was more severe and more sustained at older ages. The 
study group found the estimated NNT for routine PPI use to prevent one disabling/fatal 
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upper-GI bleed over 5 years fell from 338 at ages less than 65 years to 25 at aged 85 years 
or older.  
Professor Rothwell concluded that the long- term risks and severity of bleeding on aspirin-
based antiplatelet treatment in secondary prevention increase steeply with age51. For those 
under 75 years the risks are comparable with those reported in RCTs. In patients under 75 
years the bleeding risk is more front loaded to the first year and flattens after this time 
period. In those 75 years or older the risks of bleeding are higher, more severe and more 
sustained and the functional outcomes are far worse. In patients 75 years or older upper GI 
bleeds tend to be major disabling or fatal bleeding events. This study gave real life data on 
bleeding risks with aspirin. Professor Rothwell recommended routine PPI use to prevent 
upper-GI bleeds in patients age 75 years or over is considered for inclusion in future 
secondary prevention guidelines.  
Causes of bleeding and strategies for prevention – Professor Chris Hawkey 
Professor Hawkey explained that in contrast to non-steroidal anti-inflammatory drugs 
(NSAIDS) there is a clear clinical and epidemiological evidence that patients with the 
bacteria Helicobacter Pylori (H.Pylori) who are also taking aspirin have an increased risk of 
ulcer development and bleeding52 . This may be due to the fact one of the main actions of 
aspirin is to abrogate haemostasis and promote bleeding in lesions caused by another 
agent, e.g. H.pylori, whilst with NSAIDS it is their intrinsic ulcerogenic activity which is the 
important factor. 
Therefore two main strategies are proposed to protect against aspirin associated ulceration 
and ulcer bleeding; 
 Use of an ulcer healing agent 
 H.pylori eradication 
Ulcer healing agent: in a meta-analysis of ten RCTs involving 8780 participants PPIs were 
found to be superior to both H2 receptor antagonists and gefarnate in preventing ulceration 
or bleeding50. There are concerns about the risk of long term use of PPIs53. It is interesting 
therefore that a recent trial has found famotidine (H2 receptor antagonist) to have equal 
efficacy to a PPI54 .  
The association between H.pylori and ulcer bleeding in people taking low-dose aspirin raises 
the question as to whether the main effect of the aspirin is to enhance bleeding from the 
ulcer caused by H pylori and would therefore the eradication of the H.pylori reduce or 
eliminate upper GI bleeding on aspirin? HEAT is an ongoing study designed to test whether 
H.pylori eradication will reduce the incidence of bleeding peptic ulcers in patients taking 
aspirin55. HEAT is an outcomes study and uses cost saving innovations in the way the data 
and resources are utilised in order to save money and make it affordable. The trial is 
expected to complete in 2020.  
Professor Hawkey concluded that inducing ulcer bleeding is a most common side effect from 
aspirin use and reformulating the aspirin does not work to prevent this. PPIs are effective but 
a H2 receptor antagonist a reasonable option if a PPI cannot be used. Aspirin is anti-
haemastatic rather than ulcerogenic .  
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Concluding remarks: Professor Carlo Patrono 
Professor Patrono thanked everyone involved for a fantastic and very stimulating day 
of science and Bayer for supporting it. The presentations have illuminated aspects of 
the past history of aspirin but also most importantly its exciting potential in the future.   
“As I take over the chair of the Scientific Advisory Board of the International Aspirin 
Foundation from Professor Rothwell I look forward to the Foundation representing an 
instrument for a joint venture of the medical/scientific community and the 
pharmaceutical industry to promote further research on aspirin and its multifaceted 
actions.” 
References 
1.Li Y, Zen X, Liu J, et al. Can China achieve a one-third reduction in premature 
mortality from non-communicable diseases by 2030? BMC Medicine 2017; 15:132. 
2.China Health Statistics Yearbook 2013  
http://www.nhfpc.gov.cn/zwgkzt/tjnj/list.shtml  [accessed June 10 2014]. 
3.Yang G, Wang Y, Zeng Y, et al . Rapid health transition in China, 1990-2010: 
findings from the Global Burden of Disease Study 2010. Lancet 2013; 
381(9882):1987-2015. 
4.Human Development Unit East Asia and Pacific Region. Towards a Healthy and 
Harmonious Life in China: Stemming the Rising Tide of Non-Communicable 
Diseases. http://www.worldbankorg/content/dam/NCD_report_enpdf.2011. 
5.Zhang XF, Wang JA, Hu DY. Explanation of comparative studies on global burden 
of disease between 1990 and 2010. Zhonghua Xin Xue Guan Bing Za Zhi. 
2013;41(6):454-6. 
6.Chin J Cardiol, March 2012; Vol 40 No 3. 
7.China National Plan for NCD Prevention and Treatment (2012-2015). 
http://www.chinaede.en.en [accessed June 14, 2014]. 
8.ASCVD http://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate 
9.Kim AS. Circulation 2011; 124:314-323. 
10. NESS 2013 Nationwide Population Based Survey. Circulation 2017; 135:759-
771. 
11.Wang Y, Liu M and Pu C 2014 Chinese guidelines for secondary prevention of 
ischemic stroke and transient ischemic attack. Int J Stroke 2017; 12(3):302-320. 
15 
 
15 
 
12.Wang Y, Pan Y, Zhao X et al Clopidogrel with Aspirin in Acute Minor Stroke or 
Transient Ischemic Attack (CHANCE) Trial: One-Year outcomes [j]. Circulation 2015; 
132(1):40-46. 
13.Wang Y et al. Rationale and design of a randomized, double-blind trial comparing 
the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the 
treatment of high-risk patients with acute nondisabling cerebrovascular event[j]. 
American Heart Journal 2010; 160(3):380-386 e381. 
14.Li z, Wang Y, Zhao X et al. treatment effect of clopidogrel plus aspirin within 12 
hours of acute minor stroke or transient ischaemic attack[j]. Journal of the American 
Heart Association, 2016;5(3):e003038. 
15.Pan Y, Jing J, Chen W et al. Risks and benefits of clopidogrel-aspirin in minor 
stroke or TIA:Time course analysis of CHANCE [j]. Neurology; 2017; 88:1906-1911. 
16.Wang Y, Zhao X, Lin J et al. Association between CYP2C19 Loss-of-Function 
Allele status an efficacy of Clopidogrel for risk reduction among patients with minor 
stroke or transient ischemic attack [j] Jama; 2016, 316(1):70-78. 
17.Wei JW, Wand JG, Huang Y et al. Secondary prevention of ischemic stroke in 
urban China [j]. Stroke 2010; 41(5):967-974. 
18.Johnston SG, Gress DR, Browner WS, Sidney S. Short-term prognosis after 
emergency department diagnosis of TIA. JAMA; 2000:284:2901-2906. 
19.Coull A, Lovett JK, Rothwell PM, on behalf of the Oxford Vascular Study: 
Population based study of early risk of stroke after a transient ischaemic attack or 
minor stroke: implications for public education and organisation of services. BMJ 
2004;328: 326-328. 
20.Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a 
systematic review and meta-analysis. Lancet Neurol 2007; 6:1063-1072. 
21.Johnston SC, Rothwell PM, Nguyen-Huynh MN et al. Validation and refinement of 
scores to predict very early stroke risk after transient ischaemic attack. Lancet 
2007;369:282-292. 
22.Lasserson D, Chandratheva a, Giles MF et al. Influence of general practice 
opening hours on delay in seeking medical attention after transient ischemic attack 
(TIA) and minor stroke in 1000 consecutive patients: lessons for public education. 
Stroke 2010;41:1108-1114. 
23.Wolters FJ, Paul NL, Li L, Rothwell PM: Oxford Vascular study. Sustained impact 
of UK FAST-test public education on response to stroke: a population-based time-
series study. Int J Stroke 2015;10:1108-1114. 
16 
 
16 
 
24.Rothwell PM, Giles MF, Chandratheva A, et al. on behalf of the Early use of 
Existing Preventative Strategies for Stroke (EXPRESS) Study. Major reduction in risk 
of early recurrent stroke by urgent treatment of Tia and minor stroke: EXPRESS 
Study. Lancet 2007;370:1432-1442. 
25.Luengo-Fernandez R, Gray AM, Rothwell PM. Effect of urgent treatment for 
transient ischaemic attack and minor stroke on disability and hospital costs 
(EXPRESS study): a prospective population-based sequential comparison. Lancet 
Neurol 2009;8:235-243 
26.Rothwell PM, Algra A, Chen Z et al. Effects of aspirin on risk and severity of early 
recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course 
analysis of randomised trials. Lancet 2016;388:365-375. 
27.Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised 
trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke 
in high risk patients. Br Med j 2002;324:71-86. 
28.U.S. Preventative services Task Force. Aspirin for the prevention of 
cardiovascular disease: recommendation statement. Ann Intern Med 2009; 150:396-
404. 
29.Whitlock EP, Burda BU, Williams SB et al. Bleeding risks with aspirin use for 
primary prevention in adults: A systematic review for the U.S. Preventative Services 
Task Force. Ann Intern Med 2016; 164 (12):826-835. 
30.Nishihara R, Wu K, Lochhead P et al Long – term colorectal-cancer incidence 
and mortality after lower endoscopy. N Engl J Med 2013; 369:1095-1105.  
31.Nan H, Hutter CM Lin Y et al association of aspirin and NSAID use with risk of 
colorectal cancer according to genetic variants. JAMA 2015; 313:1133-1142. 
32.Rothwell PM, Wilson M, Elwin CE et al. Long-term effect of aspirin on colorectal 
cancer incidence and mortality: 20 year follow-up of five randomised trials. Lancet 
2010;376:1741-1750. 
33. Chan AT, Ogino S, Fuchs CS Aspirin use and survival after diagnosis of 
colorectal cancer. JAMA 2009; 302:649-658. 
34.Rothwell PM, Price JF, Fowkes FGR et al Short-term effects of daily aspirin on 
cancer incidence, mortality, and non-vascular death: analysis of the time course of 
risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602-1612. 
35.Din FV, Theodoratou E, Farrington SM et al. Effect of aspirin and NSAIDs on risk 
and survival from colorectal cancer. Gut 2010; 59:1670-1679. 
17 
 
17 
 
36.Goh CH, Leong WQ, Chew MH et al Post-operative aspirin use and colorectal 
cancer-specific survival in patients with stage I-III colorectal cancer. Anticancer Res 
2014; 34:7407-414. 
37.Li P, Wu H, Zang H et al Aspirin use after diagnosis but not prediagnosis 
improves established colorectal cancer survival: a meta-analysis. Gut 2015;64:1419-
1425. 
38.Ng K, Meyerhardt JA, Chan AT et al. Aspirin and COX-2 inhibitor use in patients 
with stage III colon cancer. Journal of the National Cancer Institute 2015; 107:345. 
39.Thun MJ, Namboodiri MM, Heath CW.Jr. Aspirin use and reduced risk of fatal 
colon cancer. The NEJM 1991;235:1593-1596. 
40.Burn J, Gerdes A-M, Macrae F et al Long-term effect of aspirin on cancer risk in 
carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised 
controlled trial  Lancet 2011; 378:2081-2087. 
41.Bloom DE, Cafiero ET, McGovern ME et al The economic impact of non-
communicable disease in China and India: estimates, Projections and Comparisons 
NBER Working Paper No.19335 August 2013. 
42. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G. Aspirin 
and cancer: has aspirin been overlooked as an adjuvant therapy? British journal of 
cancer. 2011; 105(8): 1107-13. 
43.Slater DA, Aldrovandi M, O’Connor A et al. Mapping the human platelet lipidome 
reveals cytosolic phospholipase A2 as a regulator of mitochondrial bioenergetics 
during activation. Cell metabolism 2016; 23:930-944. 
44.EMEA Position Paper on the regulatory requirements for the authorisation of low-
dose modified release ASA formulations in the secondary prevention of 
cardiovascular events. London 25 July 2002 
http://www.ema.europa.eu/docs/en_BF/document_library/Scientific_guideline/2009/0
9/WC500003340.pdf 
45.Tefferi  Barbui am J Hematol 2017; 92:94.  
46.Cavalca V, Rocca B Veglia F et al On-pump cardiac surgery enhances platelet 
renewal and impairs aspirin pharmacodynamics: effects of improved dosing 
regimens. Clin Pharmacol Ther 2017 Epub ahead of print.  
47.Peace et al JTH 2010, 8:2323. 
48.Patrono C, Rocca JACC 2017; 69:213. 
18 
 
18 
 
49.Antithrombotic trialists Baigent C, Blackwell L et al Aspirin in the primary and 
secondary prevention of vascular disease: collaborative meta-analysis of individual 
participant data from randomised trials. Lancet 2009; 373:1849-1860. 
50.Mo C, Sun G, Lu ML et al Proton pump inhibitors in prevention of low-dose 
aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 2015; 
21:5382-5392. 
51. Li L, Geraghty OC, Mehta Z et al Oxford Vascukar Study. Age-specific risks, 
severity, time-course, and outcome of bleeding on long-term antiplatelet treatment 
after vascular events:a population-based cohort study. Lancet 2017;390:490-499. 
52.Cullen DJ, Hawkey GM, Greenwood DC et al Peptic ulcer bleeding in the elderly: 
relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. GUT 
1997;41(4):459-462. 
53.Freedberg DE, Kim LS, Yang YX The risks and benefits of long-term use of 
proton pump inhibitors: Expert review and best practice advice from the American 
Gastroenterological Association. [Review] Gastroenterology  2017;152(4):706-715. 
54. Vaduganathan M, Cannon CP, Cryer BL et al COGENT Investigators. Efficacy 
and safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the 
COGENT Trial. American Journal of Medicine. 2016: 129(9):1002-1005. 
55. Chan FK, Chung SC, Suen BY et al Preventing recurrent upper gastrointestinal 
bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin 
or naproxen. New England Journal of Medicine 2001; 344(13):967-973.  
